Navigation Links
Aratana Therapeutics Announces Full Exercise of Over-Allotment Option
Date:7/11/2013

KANSAS CITY, Kan. and BOSTON, July 11, 2013 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative prescription medications for pets, today announced the full exercise of the over-allotment option granted to the underwriters to purchase 862,500 additional shares of common stock, at a public offering price of $6.00 per share, in connection with its previously announced initial public offering of 5,750,000 shares of common stock that closed on July 2, 2013, bringing the total gross proceeds from the offering to $39,675,000, before deducting the underwriting discounts and commissions and other offering expenses payable by Aratana Therapeutics.  The company's common stock is listed on The NASDAQ Global Market under the trading symbol "PETX."

Stifel and Lazard Capital Markets acted as lead book-running managers for the offering.  William Blair, JMP Securities and Craig-Hallum Capital Group acted as co-managers.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on June 26, 2013.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful.

The offering is being made only by means of a written prospectus forming part of the effective registration statement.  Copies of the prospectus related to the offering may be obtained from Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by callin
'/>"/>

SOURCE Aratana Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aratana Therapeutics Completes $15 Million Series B Financing
2. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
3. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
4. Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
5. Aratana Therapeutics Adds To Drug Development Team
6. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
7. Nile Therapeutics Reports 2011 Third Quarter Financial Results
8. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
9. Fate Therapeutics Strengthens Its iPSC Platform
10. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
11. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... Die SARAH-Studie ... Assistance Publique - Hôpitaux de ... französische, gemeinschaftliche, randomisierte Kontrollstudie für die mehr ... werden Patienten mit fortgeschrittenem hepatozellulärem Karzinom (HCC), ... behandelt wurden. Die Ergebnisse werden für Ende ...
(Date:3/5/2015)... March 5, 2015   HX360 today announced ... the HX360 Innovation Challenge competition. These companies, ... to be chosen as one of four finalists to ... health system executives and venture capitalists during the Innovation ... takes place at the 2015 HIMSS Annual Conference & ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 BioPlus Specialty ... the position of Vice President of Managed Care. In ... relationships for one of the nation’s leading specialty pharmacies. ... than 15 years of specialty pharmacy and biotech experience ... with Raptor Pharmaceuticals, Vertex Pharmaceuticals, and Pfizer. Prior to ...
(Date:3/5/2015)... and TORONTO , March 5, 2015 ... clinical-stage company developing new therapeutics and molecular diagnostics that ... William G. Rice , Ph.D., Chairman, President and ... Annual ROTH Conference on Tuesday, March 10 th ... Laguna Niguel, CA. Dr. Rice ...
Breaking Biology Technology:Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3
... 2011 Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) ... systems, announced today that its work entitled "Evaluation of ... in Healthy Volunteers" will be presented at the Eleventh ... held in San Francisco, California. "The selection ...
... N.J., Oct. 25, 2011 Quest Diagnostics Incorporated (NYSE: ... has begun the process of identifying a successor to Surya ... Board of Directors has formed a search committee, engaged a ... internal candidates. Dr. Mohapatra has agreed to ...
... Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in ... update on operations and disclosed the outcome of a ... by management and AMT,s Board of Directors that enables ... therapy development. The CHMP,s recent opinion, while not approving ...
Cached Biology Technology:Oramed Pharmaceuticals Chosen to Present at the Diabetes Technology Meeting (October 27-29, 2011; San Francisco, CA) 2Quest Diagnostics Initiates CEO Succession Process 2Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline 2Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline 3Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline 4
(Date:2/12/2015)... MINNETONKA, Minn. , Feb. 12, 2015 /PRNewswire/ ... technology company specializing in clinical study management systems, ... Partner Program , further distinguishing iMedNet ... for Clinical Research Organizations (CROs) and healthcare consultants.  ... sales support, prospective customer referrals and numerous co-marketing ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, North Carolina , ... in sein 35. Jahr als spezialisiertes Logistikunternehmen ... seine Position als einzige klinische Logistikfirma (Clinical ... soll. Die Kernbotschaft der neuen Kampagne lautet ... Protokollen und Lieferungen. Foto: ...
(Date:2/5/2015)... 2015 New Market Research Reports ... Forecasts To 2020 has Been Added to GrandViewReseach.com Report ... expected to reach USD 5.10 billion by 2020, according ... IR cameras help identify the site of tissue damage ... surging demand in medical imaging applications. They have been ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... trigger warning signals in our cells. As a result, genes ... to the external danger and to protect the organism. In ... corresponding DNA segment, the gene, needs to be expressed and ... exists as a long string that is coiled and bound ...
... Elsevier, a world-leading provider of scientific, technical and ... entered into an agreement with the American Association for ... of Geriatric Psychiatry (AJGP) beginning in January 2013. ... this relationship with Elsevier," commented Chris M. deVries, Chief ...
... Although the two disorders may seem dissimilar, epilepsy and ... to have schizophrenia, and a family history of epilepsy ... known whether the converse is true, i.e., whether a ... epilepsy. Multiple studies using varied investigative techniques ...
Cached Biology News:A small cut with a big impact 2Elsevier selected as new publisher of the American Journal of Geriatric Psychiatry 2Evidence of familial vulnerability for epilepsy and psychosis 2
Topoisomerase I...
... I from vaccinia virus is a type ... and negative superhelical turns (also called right- ... The product of the reaction is a ... or negative superhelical turns. DNA Topoisomerase I ...
...
... Topoisomerase I from vaccinia virus is a ... positive and negative superhelical turns (also called ... DNA. The product of the reaction is ... positive or negative superhelical turns. DNA Topoisomerase ...
Biology Products: